)
)
Prostate Cancer Polygenic Risk Scores in Clinic - Where are we and where do we go from here?
-
The currently used clinical test for prostate cancer (PSA) has high false positive rates, particularly in Black men
-
Proteomic estimation of the PSA test combined with polygenic scores improves predictive accuracy, but racial disparities remain
-
More data is needed on the best ways to implement polygenic scores without exacerbating existing health inequities
